Email this article Exosomal microRNAs in colorectal cancer diagnostics
- Authors: Serbaeva M.S.1,2, Vorobyev S.A.3, Ruksha T.G.2, Zukov R.A.1,2
-
Affiliations:
- Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky, Krasnoyarsk, Russia
- Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
- Krasnoyarsk Science Centre of the Siberian Branch of Russian Academy of Science, Krasnoyarsk, Russia
- Section: Original Study Articles
- Submitted: 17.12.2024
- Accepted: 14.05.2025
- Published: 20.05.2025
- URL: https://rjonco.com/1028-9984/article/view/643119
- DOI: https://doi.org/10.17816/onco643119
- ID: 643119
Cite item
Open Access
Access granted
Abstract
BACKGROUND: Global statistics demonstrate an upward trend in colorectal cancer (CRC) incidence and mortality, especially in developed and developing countries, in young working-age individuals under 50 years of age, which makes the search for non-invasive CRC markers relevant.
AIM: To identify target exosomal microRNAs for CRC diagnostics in patients over and under 50 years of age.
MATERIALS AND METHODS: Next-generation sequencing (NGS) of blood plasma samples from 10 patients with CRC was performed, followed by an assessment of the hydrodynamic size of exosomes using dynamic light scattering in three samples.
RESULTS: Nine molecules of exosomal microRNAs most characteristic of CRC patients were identified. For patients over 50 years old: miR-26 b, miR-124-1, miR-518 b, miR-520 d, miR-518 d, miR-612, miR-1283-1, miR-1260 a, for patients under 50 years old: miR-4510.
CONCLUSIONS. Non-invasive diagnostics of colorectal cancer using exosomal microRNAs has a high diagnostic potential in individuals of different age groups, but given the difficult-to-reproduce methodology in routine clinical practice, it requires further scientific research.
Full Text
About the authors
Margarita S. Serbaeva
Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky, Krasnoyarsk, Russia; Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
Email: serbaeva94@mail.ru
ORCID iD: 0009-0007-3268-2535
SPIN-code: 4662-4362
Radiotherapist at the Radiotherapy Department No. 2, Assistant at the Department of Oncology and Radiation Therapy with a course PO
Russian Federation, Krasnoyarsk, Russia; Krasnoyarsk, RussiaSergei A. Vorobyev
Krasnoyarsk Science Centre of the Siberian Branch of Russian Academy of Science, Krasnoyarsk, Russia
Email: yekspatz@yandex.ru
SPIN-code: 7747-0299
MD, Cand. Sci. (Medicine)
Russian Federation, Krasnoyarsk, RussiaTatyana G. Ruksha
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
Email: tatyana_ruksha@mail.ru
ORCID iD: 0000-0001-8142-4283
SPIN-code: 5412-2148
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Krasnoyarsk, RussiaRuslan A. Zukov
Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky, Krasnoyarsk, Russia; Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia
Author for correspondence.
Email: zukov.ra@krasgmu.ru
ORCID iD: 0000-0002-7210-3020
SPIN-code: 3632-8415
ResearcherId: A-8193-2016
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Krasnoyarsk, Russia; Krasnoyarsk, RussiaReferences
- Maksimova PE, Golubinskaya EP, Seferov BD, Zyablitskaya EYu. Colorectal cancer: epidemiology, carcinogenesis, molecular subtypes and cellular mechanisms of therapy resistance (analytical review). Koloproktologia. 2023;22(2):160–171. doi: 10.33878/2073-7556-2023-22-2-160-171
- Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Current Drug Targets. 2021;22(9):998–1009. doi: 10.2174/1389450121999201117115717
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–263. doi: 10.3322/caac.21834
- Venugopal A, Carethers JM. Epidemiology and biology of early onset colorectal cancer. EXCLI J. 2022;21:162–182. doi: 10.17179/excli2021-4456
- Ullah F, Pillai AB, Omar N, et al. Early-Onset Colorectal Cancer: Current Insights. Cancers. 2023;15(12):3202. doi: 10.3390/cancers15123202
- O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. The American Journal of Surgery. 2004;187(3):343–348. doi: 10.1016/j.amjsurg.2003.12.020
- Ma J, Wang P, Huang L, et al. Bioinformatic analysis reveals an exosomal miRNA-mRNA network in colorectal cancer. BMC Med Genomics. 2021;14:60. doi: 10.1186/s12920-021-00905-2
- Gasparello J, Papi C, Allegretti M, et al. A Distinctive microRNA (miRNA) Signature in the Blood of Colorectal Cancer (CRC) Patients at Surgery. Cancers. 2020;12(9):2410. doi: 10.3390/cancers12092410
- Liu J, Ren L, Li S, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11(9):2783–2797. doi: 10.1016/j.apsb.2021.01.001
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. doi: 10.1126/science.aau6977
- Mezher M, Abdallah S, Ashekyan O, et al. Insights on the Biomarker Potential of Exosomal Non-Coding RNAs in Colorectal Cancer: An In Silico Characterization of Related Exosomal lncRNA/circRNA–miRNA–Target Axis. Cells. 2023;12(7):1081. doi: 10.3390/cells12071081
- Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. PLoS ONE. 2014;9:e92921. doi: 10.1371/journal.pone.0092921
- Dokhanchi M, Pakravan K, Zareian S, et al. Colorectal cancer cell-derived extracellular vesicles transfer miR-221-3p to promote endothelial cell angiogenesis via targeting suppressor of cytokine signaling 3. Life Sci. 2021;285:119937. doi: 10.1016/j.lfs.2021.119937
- Min L, Chen L, Liu S, et al. Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage. Int. J. Med. Sci. 2019;16(9):1231–1237. doi: 10.7150/ijms.34540
- Wang J, Liu Y, Li Y, et al. Exosomal-miR-10a derived from colorectal cancer cells suppresses migration of human lung fibroblasts, and expression of IL-6, IL-8 and IL-1β. Mol. Med. Rep. 2021;23(1):84. doi: 10.3892/mmr.2020.11723
- Yan S, Jiang Y, Liang C, et al. Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer. J Cell Biochem. 2018;119(5):4113–4119. doi: 10.1002/jcb.26609
- Yang D, Zhang W, Zhang H, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics. 2020;10(8):3684–3707. doi: 10.7150/thno.41580
- Moazeni-Roodi A, Hashemi M. Association between miR-124-1 rs531564 polymorphism and risk of cancer: An updated meta-analysis of case-control studies. EXCLI J. 2018;17:608–619. doi: 10.17179/excli2018-1419
- Zhang M, Zhou S, Zhang L, et al. miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma [retracted in: FEBS Lett. 2023;597(21):2699]. FEBS Lett. 2012;586(19):3508–3521. doi: 10.1016/j.febslet.2012.08.007
- Zhang X, Hu Y, Gong C, Zhang C. Overexpression of miR-518b in non-small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion. Oncol Lett. 2020;20(2):1213–1220. doi: 10.3892/ol.2020.11667
- Miura K, Higashijima A, Mishima H, et al. Pregnancy-associated microRNAs in plasma as potential molecular markers of ectopic pregnancy. Fertility and Sterility. 2015;103(5):1202–1208.e1. doi: 10.1016/j.fertnstert.2015.01.041
- Li JS, Liu TM, Li L, Jiang C. LncRNA PROX1 antisense RNA 1 promotes PD-L1-mediated proliferation, metastasis, and immune escape in colorectal cancer by interacting with miR-520d. Anticancer Drugs. 2023;34(5):669–679. doi: 10.1097/CAD.0000000000001437
- Sheng L, He P, Yang X, et al. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell Death Dis. 2015;6(7):e1808. doi: 10.1038/cddis.2015.184
- Chang J, Tian J, Yang Y, et al. A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer. Cancer Res. 2018;78(17):5164–5172. doi: 10.1158/0008-5472.CAN-18-0910
Supplementary files
